{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:35:30Z","timestamp":1792197330135,"version":"4.4.0"},"reference-count":142,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["24-75-00061"],"award-info":[{"award-number":["24-75-00061"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Adeno-associated viral vectors have proven to be a safe and effective gene therapy delivery system. Over the past decade, the approval of AAV gene therapies made a revolution in treatment of severe hereditary diseases, including spinal muscular atrophy, AADC deficiency, and others. Recombinant AAV-based therapeutics are currently intended for single administration. Safety concerns arise from immune responses to AAV and the resulting transgene, which can render subsequent injections ineffective. It remains unclear whether patients who have received an AAV-based gene therapy will need re-administration in the future. Furthermore, since many people have neutralizing antibodies or memory T cells against AAV from natural infections, it is crucial to overcome pre-existing immunity. This review considers existing modern approaches aimed to overcome both pre-existing natural immunity and immunity obtained after the administration of a gene therapy drug, which include various modifications of the viral drug (capsid modification, codon optimization), the use of empty capsid traps, and pharmacological support (immunosuppressive corticosteroids, inhibitors of various branches of the immune response, nanoparticles, IgG-degrading enzymes). The goal of this review is to illustrate the importance of this challenge and to highlight potential strategies for overcoming immunity to AAV-based gene therapies, contributing to the development of a successful therapeutic gene delivery platform.<\/jats:p>","DOI":"10.3390\/pharmaceutics17111492","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T10:02:13Z","timestamp":1763546533000},"page":"1492","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Emerging Technologies Tackling Adeno-Associated Viruses (AAV) Immunogenicity in Gene Therapy Applications"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3346-3242","authenticated-orcid":false,"given":"Tatiana","family":"Egorova","sequence":"first","affiliation":[{"name":"Laboratory of Modeling and Therapy of Hereditary Diseases, Institute of Gene Biology Russian Academy of Sciences, 119334 Moscow, Russia"},{"name":"Marlin Biotech LLC, 354340 Sochi, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2648-5582","authenticated-orcid":false,"given":"Anna","family":"Starikova","sequence":"additional","affiliation":[{"name":"Laboratory of Modeling and Therapy of Hereditary Diseases, Institute of Gene Biology Russian Academy of Sciences, 119334 Moscow, Russia"},{"name":"Marlin Biotech LLC, 354340 Sochi, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9442-8371","authenticated-orcid":false,"given":"Anna","family":"Polikarpova","sequence":"additional","affiliation":[{"name":"Laboratory of Modeling and Therapy of Hereditary Diseases, Institute of Gene Biology Russian Academy of Sciences, 119334 Moscow, Russia"},{"name":"Marlin Biotech LLC, 354340 Sochi, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2174\/1566523214666140302193709","article-title":"Basic Biology of Adeno-Associated Virus (AAV) Vectors Used in Gene Therapy","volume":"14","author":"Balakrishnan","year":"2014","journal-title":"Curr. Gene Ther."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Geng, G., Xu, Y., Hu, Z., Wang, H., Chen, X., Yuan, W., and Shu, Y. (2025). Viral and Non-Viral Vectors in Gene Therapy: Current State and Clinical Perspectives. eBioMedicine, 118.","DOI":"10.1016\/j.ebiom.2025.105834"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1089\/hum.2017.150","article-title":"Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After Trial","volume":"28","author":"Vandamme","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune Responses to AAV Vectors: Overcoming Barriers to Successful Gene Therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Ronzitti, G., Gross, D.-A., and Mingozzi, F. (2020). Human Immune Responses to Adeno-Associated Virus (AAV) Vectors. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.00670"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrg2988","article-title":"Therapeutic in Vivo Gene Transfer for Genetic Disease Using AAV: Progress and Challenges","volume":"12","author":"Mingozzi","year":"2011","journal-title":"Nat. Rev. Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8+ T-Cell Responses to Adeno-Associated Virus Capsid in Humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100915","DOI":"10.1016\/j.preteyeres.2020.100915","article-title":"Immune Responses to Retinal Gene Therapy Using Adeno-Associated Viral Vectors\u2014Implications for Treatment Success and Safety","volume":"83","author":"Bucher","year":"2021","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","article-title":"Lethal Immunotoxicity in High-Dose Systemic AAV Therapy","volume":"31","author":"Duan","year":"2023","journal-title":"Mol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3349\/ymj.2011.52.3.379","article-title":"Intrinsic and Extrinsic Regulation of Innate Immune Receptors","volume":"52","author":"Jeong","year":"2011","journal-title":"Yonsei Med. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jmb.2013.11.024","article-title":"Toll-Like Receptors in Antiviral Innate Immunity","volume":"426","author":"Lester","year":"2014","journal-title":"J. Mol. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40259-023-00585-7","article-title":"Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer","volume":"37","author":"Arjomandnejad","year":"2023","journal-title":"BioDrugs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"103997","DOI":"10.1016\/j.cellimm.2019.103997","article-title":"TLR9 Signaling Mediates Adaptive Immunity Following Systemic AAV Gene Therapy","volume":"346","author":"Ashley","year":"2019","journal-title":"Cell. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Li, N., Kumar, S.R.P., Cao, D., Munoz-Melero, M., Arisa, S., Brian, B.A., Greenwood, C.M., Yamada, K., Duan, D., and Herzog, R.W. (2024). Redundancy in Innate Immune Pathways That Promote CD8+ T-Cell Responses in AAV1 Muscle Gene Transfer. Viruses, 16.","DOI":"10.3390\/v16101507"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Bertolini, T.B., Shirley, J.L., Zolotukhin, I., Li, X., Kaisho, T., Xiao, W., Kumar, S.R.P., and Herzog, R.W. (2021). Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.672449"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Artemyev, V., Gubaeva, A., Paremskaia, A.I., Dzhioeva, A.A., Deviatkin, A., Feoktistova, S.G., Mityaeva, O., and Volchkov, P.Y. (2024). Synthetic Promoters in Gene Therapy: Design Approaches, Features and Applications. Cells, 13.","DOI":"10.3390\/cells13231963"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41434-021-00296-0","article-title":"Rational Engineering of a Functional CpG-Free ITR for AAV Gene Therapy","volume":"29","author":"Pan","year":"2022","journal-title":"Gene Ther."},{"key":"ref_18","first-page":"e120474","article-title":"Double-Stranded RNA Innate Immune Response Activation from Long-Term Adeno-Associated Virus Vector Transduction","volume":"13","author":"Shao","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"eads6498","DOI":"10.1126\/sciadv.ads6498","article-title":"Effective Recognition of Double-Stranded RNA Does Not Require Activation of Cellular Inflammation","volume":"11","author":"Drazkowska","year":"2025","journal-title":"Sci. Adv."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Rapti, K., and Grimm, D. (2021). Adeno-Associated Viruses (AAV) and Host Immunity\u2014A Race Between the Hare and the Hedgehog. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.753467"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1089\/hum.2022.138","article-title":"Immune Responses and Immunosuppressive Strategies for Adeno-Associated Virus-Based Gene Therapy for Treatment of Central Nervous System Disorders: Current Knowledge and Approaches","volume":"33","author":"Prasad","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Merle, N.S., Church, S.E., Fremeaux-Bacchi, V., and Roumenina, L.T. (2015). Complement System Part I\u2014Molecular Mechanisms of Activation and Regulation. Front. Immunol., 6.","DOI":"10.3389\/fimmu.2015.00262"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1089\/hum.2024.040","article-title":"Innate Immune Sensing of Adeno-Associated Virus Vectors","volume":"35","author":"Cao","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1128\/JVI.01990-07","article-title":"Complement Is an Essential Component of the Immune Response to Adeno-Associated Virus Vectors","volume":"82","author":"Zaiss","year":"2008","journal-title":"J. Virol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1089\/hum.2023.194","article-title":"Complement System Response to Adeno-Associated Virus Vector Gene Therapy","volume":"35","author":"Kropf","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e143780","DOI":"10.1172\/JCI143780","article-title":"Overcoming Innate Immune Barriers That Impede AAV Gene Therapy Vectors","volume":"131","author":"Muhuri","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"101551","DOI":"10.1016\/j.omtm.2025.101551","article-title":"Innate Immune Response to AAV-Based Gene Therapy Vectors: Mechanisms of Complement Activation and Cytokine Release","volume":"33","author":"Xicluna","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_29","unstructured":"(2025, November 01). Previous Annual Meetings|ASGCT Annual Meeting. Available online: https:\/\/annualmeeting.asgct.org\/about\/previous-annual-meetings."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0074-7696(06)50006-3","article-title":"Cell Biology of T Cell Activation and Differentiation","volume":"250","author":"Santana","year":"2006","journal-title":"Int. Rev. Cytol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful Transduction of Liver in Hemophilia by AAV-Factor IX and Limitations Imposed by the Host Immune Response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-Associated Virus Vector-Mediated Gene Transfer in Hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant","volume":"377","author":"George","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"15029","DOI":"10.1038\/mtm.2015.29","article-title":"AAV Capsid CD8+ T-Cell Epitopes Are Highly Conserved across AAV Serotypes","volume":"2","author":"Hui","year":"2015","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.4049\/jimmunol.172.11.6658","article-title":"Elimination of an Immunodominant CD4+ T Cell Epitope in Human IFN-Beta Does Not Result in an in Vivo Response Directed at the Subdominant Epitope","volume":"172","author":"Yeung","year":"2004","journal-title":"J. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/j.1538-7836.2005.01309.x","article-title":"Identification and Removal of a Promiscuous CD4+ T Cell Epitope from the C1 Domain of Factor VIII","volume":"3","author":"Jones","year":"2005","journal-title":"J. Thromb. Haemost. JTH"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","article-title":"Dystrophin Immunity in Duchenne\u2019s Muscular Dystrophy","volume":"363","author":"Mendell","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMc2212912","article-title":"Dystrophin Immunity after Gene Therapy for Duchenne\u2019s Muscular Dystrophy","volume":"388","author":"Belluscio","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_39","unstructured":"Pfizer (2025, August 07). A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of Pf 06939926 for the Treatment of Duchenne Muscular Dystrophy; Clinical Trial Registration NCT04281485; Clinicaltrials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04281485."},{"key":"ref_40","unstructured":"Sarepta Therapeutics, Inc (2025, August 07). An Open-Label, Systemic Gene Delivery Study Using Commercial Process Material to Evaluate the Safety of and Expression from SRP-9001 in Subjects with Duchenne Muscular Dystrophy (ENDEAVOR); Clinical Trial Registration NCT04626674; Clinicaltrials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04626674."},{"key":"ref_41","unstructured":"(2025, August 07). Clinical Trials Register\u2014Search for 2020-002093-27. Available online: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2020-002093-27."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1089\/hum.2021.135","article-title":"Intracerebral Gene Therapy in Four Children with Sanfilippo B Syndrome: 5.5-Year Follow-Up Results","volume":"32","author":"Deiva","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jneuroim.2003.11.013","article-title":"Thymic Myoid Cells Express High Levels of Muscle Genes","volume":"148","author":"Bismuth","year":"2004","journal-title":"J. Neuroimmunol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1038\/s41591-019-0594-0","article-title":"Non-Immunogenic Utrophin Gene Therapy for the Treatment of Muscular Dystrophy Animal Models","volume":"25","author":"Song","year":"2019","journal-title":"Nat. Med."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Starikova, A.V., Skopenkova, V.V., Polikarpova, A.V., Reshetov, D.A., Vassilieva, S.G., Velyaev, O.A., Shmidt, A.A., Savchenko, I.M., Soldatov, V.O., and Egorova, T.V. (2022). Therapeutic Potential of Highly Functional Codon-Optimized Microutrophin for Muscle-Specific Expression. Sci. Rep., 12.","DOI":"10.1038\/s41598-022-04892-x"},{"key":"ref_46","unstructured":"FDA (2025, June 20). Approved Cellular and Gene Therapy Products, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/approved-cellular-and-gene-therapy-products."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of Serum IgG and Neutralizing Factors against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1128\/iai.2.6.716-722.1970","article-title":"Seroepidemiological and Ecological Studies of the Adenovirus-Associated Satellite Viruses","volume":"2","author":"Parks","year":"1970","journal-title":"Infect. Immun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2023.01.010","article-title":"Binding and Neutralizing Anti-AAV Antibodies: Detection and Implications for rAAV-Mediated Gene Therapy","volume":"31","author":"Schulz","year":"2023","journal-title":"Mol. Ther."},{"key":"ref_50","unstructured":"FDA (2025, June 28). List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools), Available online: https:\/\/www.fda.gov\/medical-devices\/in-vitro-diagnostics\/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1182\/bloodadvances.2023010511","article-title":"Hemophilia B and Gene Therapy: A New Chapter with Etranacogene Dezaparvovec","volume":"8","author":"Anguela","year":"2024","journal-title":"Blood Adv."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/rth2.12177","article-title":"Adenovirus-associated Antibodies in UK Cohort of Hemophilia Patients: A Seroprevalence Study of the Presence of Adenovirus-associated Virus Vector\u2013Serotypes AAV5 and AAV8 Neutralizing Activity and Antibodies in Patients with Hemophilia A","volume":"3","author":"Stanford","year":"2019","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.omtm.2022.02.011","article-title":"Testing Preexisting Antibodies Prior to AAV Gene Transfer Therapy: Rationale, Lessons and Future Considerations","volume":"25","author":"Mendell","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1208\/s12248-023-00814-5","article-title":"Evaluation of Cellular Immune Response to Adeno-Associated Virus-Based Gene Therapy","volume":"25","author":"Gorovits","year":"2023","journal-title":"AAPS J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1089\/hum.2023.225","article-title":"Prevalence Study of Cellular Capsid-Specific Immune Responses to AAV2, 4, 5, 8, 9, and Rh10 in Healthy Donors","volume":"35","author":"Xicluna","year":"2024","journal-title":"Hum. Gene Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/gt.2012.43","article-title":"Efficacy and Long-Term Safety of Alipogene Tiparvovec (AAV1-LPLS447X) Gene Therapy for Lipoprotein Lipase Deficiency: An Open-Label Trial","volume":"20","author":"Gaudet","year":"2013","journal-title":"Gene Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.ophtha.2019.06.017","article-title":"Efficacy, Safety, and Durability of Voretigene Neparvovec-Rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials","volume":"126","author":"Maguire","year":"2019","journal-title":"Ophthalmology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"100817","DOI":"10.1016\/j.lanepe.2023.100817","article-title":"Efficacy and Safety of Onasemnogene Abeparvovec in Children with Spinal Muscular Atrophy Type 1: Real-World Evidence from 6 Infusion Centres in the United Kingdom","volume":"37","author":"Gowda","year":"2024","journal-title":"Lancet Reg. Health Eur."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Fernandes, B.D., Krug, B.C., Rodrigues, F.D., Cirilo, H.N.C., Borges, S.S., Schwartz, I.V.D., Probst, L.F., and Zimmermann, I. (2024). Efficacy and Safety of Onasemnogene Abeparvovec for the Treatment of Patients with Spinal Muscular Atrophy Type 1: A Systematic Review with Meta-Analysis. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0302860"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e210268","DOI":"10.1212\/WNL.0000000000210268","article-title":"Safety and Efficacy of IV Onasemnogene Abeparvovec for Pediatric Patients with Spinal Muscular Atrophy: The Phase 3b SMART Study","volume":"104","author":"McMillan","year":"2025","journal-title":"Neurology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity Following Administration of Onasemnogene Abeparvovec (AVXS-101) for the Treatment of Spinal Muscular Atrophy","volume":"74","author":"Chand","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1016\/S2352-3026(24)00006-1","article-title":"Etranacogene Dezaparvovec Gene Therapy for Haemophilia B (HOPE-B): 24-Month Post-Hoc Efficacy and Safety Data from a Single-Arm, Multicentre, Phase 3 Trial","volume":"11","author":"Coppens","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"102615","DOI":"10.1016\/j.rpth.2024.102615","article-title":"Efficacy, Safety, and Quality of Life 4 Years after Valoctocogene Roxaparvovec Gene Transfer for Severe Hemophilia A in the Phase 3 GENEr8-1 Trial","volume":"8","author":"Leavitt","year":"2024","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/j.ymthe.2024.05.033","article-title":"Clinical Immunogenicity Outcomes from GENEr8-1, a Phase 3 Study of Valoctocogene Roxaparvovec, an AAV5-Vectored Gene Therapy for Hemophilia A","volume":"32","author":"Long","year":"2024","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/s41591-024-03304-z","article-title":"AAV Gene Therapy for Duchenne Muscular Dystrophy: The EMBARK Phase 3 Randomized Trial","volume":"31","author":"Mendell","year":"2025","journal-title":"Nat. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ymthe.2021.11.005","article-title":"Long-Term Efficacy and Safety of Eladocagene Exuparvovec in Patients with AADC Deficiency","volume":"30","author":"Tai","year":"2022","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1056\/NEJMoa2307159","article-title":"Fidanacogene Elaparvovec for Hemophilia B\u2014A Multiyear Follow-up Study","volume":"392","author":"Rasko","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Gross, D.-A., Tedesco, N., Leborgne, C., and Ronzitti, G. (2022). Overcoming the Challenges Imposed by Humoral Immunity to AAV Vectors to Achieve Safe and Efficient Gene Transfer in Seropositive Patients. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.857276"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"194ra92","DOI":"10.1126\/scitranslmed.3005795","article-title":"Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys","volume":"5","author":"Mingozzi","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"17562864221149781","DOI":"10.1177\/17562864221149781","article-title":"Evaluation of rAAVrh74 Gene Therapy Vector Seroprevalence by Measurement of Total Binding Antibodies in Patients with Duchenne Muscular Dystrophy","volume":"16","author":"Goedeker","year":"2023","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.copbio.2019.01.002","article-title":"Engineering the AAV Capsid to Evade Immune Responses","volume":"60","author":"Barnes","year":"2019","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Selot, R., Arumugam, S., Mary, B., Cheemadan, S., and Jayandharan, G.R. (2017). Optimized AAV Rh.10 Vectors That Partially Evade Neutralizing Antibodies during Hepatic Gene Transfer. Front. Pharmacol., 8.","DOI":"10.3389\/fphar.2017.00441"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2012-10-460733","article-title":"Engineered AAV Vector Minimizes in Vivo Targeting of Transduced Hepatocytes by Capsid-Specific CD8+ T Cells","volume":"121","author":"Martino","year":"2013","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1038\/s41467-025-59088-4","article-title":"Structural Characterization of Antibody-Responses Following Zolgensma Treatment for AAV Capsid Engineering to Expand Patient Cohorts","volume":"16","author":"Mietzsch","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Wang, H., Hao, X., He, Y., and Fan, L. (2024). AbImmPred: An Immunogenicity Prediction Method for Therapeutic Antibodies Using AntiBERTy-Based Sequence Features. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0296737"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/978-1-4939-6637-0_20","article-title":"EpiSweep: Computationally-Driven Reengineering of Therapeutic Proteins to Reduce Immunogenicity While Maintaining Function","volume":"1529","author":"Choi","year":"2017","journal-title":"Methods Mol. Biol. Clifton NJ"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.omtn.2017.06.011","article-title":"Rationally Engineered AAV Capsids Improve Transduction and Volumetric Spread in the CNS","volume":"8","author":"Kanaan","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/gt.2016.75","article-title":"Direct Interaction of Human Serum Proteins with AAV Virions to Enhance AAV Transduction: Immediate Impact on Clinical Applications","volume":"24","author":"Wang","year":"2017","journal-title":"Gene Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41434-019-0107-2","article-title":"An Engineered Serum Albumin-Binding AAV9 Capsid Achieves Improved Liver Transduction after Intravenous Delivery in Mice","volume":"27","author":"Jin","year":"2020","journal-title":"Gene Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.ymthe.2023.06.009","article-title":"Re-Administration of AAV Vectors by Masking with Host Albumin: A Goldilocks Hypothesis","volume":"31","author":"Wright","year":"2023","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"16049","DOI":"10.1038\/mtm.2016.49","article-title":"A Translationally Optimized AAV-UGT1A1 Vector Drives Safe and Long-Lasting Correction of Crigler-Najjar Syndrome","volume":"3","author":"Ronzitti","year":"2016","journal-title":"Mol. Ther.\u2014Methods Clin. Dev."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"160810","DOI":"10.1016\/j.cej.2025.160810","article-title":"Nanovaccine Enables Complement System Inhibition and High-Dose AAV Re-Administration","volume":"507","author":"Liao","year":"2025","journal-title":"Chem. Eng. J."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"101205","DOI":"10.1016\/j.omtm.2024.101205","article-title":"AAV Gene Therapy in Companion Dogs with Severe Hemophilia: Real-World Long-Term Data on Immunogenicity, Efficacy, and Quality of Life","volume":"32","author":"Doshi","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41587-020-0741-7","article-title":"A Long-Term Study of AAV Gene Therapy in Dogs with Hemophilia A Identifies Clonal Expansions of Transduced Liver Cells","volume":"39","author":"Nguyen","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.ymthe.2022.03.004","article-title":"Durability of Transgene Expression after rAAV Gene Therapy","volume":"30","author":"Muhuri","year":"2022","journal-title":"Mol. Ther."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/j.ymthe.2025.03.043","article-title":"Gene Therapy for Hemophilia\u2014From Basic Science to First Approvals of \u201cOne-and-Done\u201d Therapies","volume":"33","author":"Herzog","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_87","unstructured":"(2025, August 04). Novartis Shares Zolgensma Long-Term Data Demonstrating Sustained Durability Up to 7.5 Years Post-Dosing; 100% Achievement of All Assessed Milestones in Children Treated Prior to SMA Symptom Onset|Novartis. Available online: https:\/\/www.novartis.com\/news\/media-releases\/novartis-shares-zolgensma-long-term-data-demonstrating-sustained-durability-75-years-post-dosing-100-achievement-all-assessed-milestones-children-treated-prior-sma-symptom-onset."},{"key":"ref_88","unstructured":"Waldrop, M.A. (2025, January 16\u201319). Long-Term Follow-Up of Onasemnogene Abeparvovec Gene Therapy for Patients with Spinal Muscular Atrophy Type 1 from the START Trial. Proceedings of the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, Dallas, TX, USA."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1089\/hum.2022.190","article-title":"Microdystrophin Expression as a Surrogate Endpoint for Duchenne Muscular Dystrophy Clinical Trials","volume":"34","author":"Chamberlain","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"104441","DOI":"10.1016\/j.nmd.2024.07.305","article-title":"425P Five-Year Outcomes with Delandistrogene Moxeparvovec in Patients with Duchenne Muscular Dystrophy (DMD): A Phase 1\/2a Study","volume":"43","author":"Mendell","year":"2024","journal-title":"Neuromuscul. Disord."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1016\/j.ymthe.2025.04.045","article-title":"Current Clinical Applications of AAV-Mediated Gene Therapy","volume":"33","author":"Byrne","year":"2025","journal-title":"Mol. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1172\/JCI115025","article-title":"Intravenous Administration of Phosphorylated Acid Alpha-Glucosidase Leads to Uptake of Enzyme in Heart and Skeletal Muscle of Mice","volume":"87","author":"Kroos","year":"1991","journal-title":"J. Clin. Investig."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1006\/mthe.2002.0580","article-title":"Correction of the Enzymatic and Functional Deficits in a Model of Pompe Disease Using Adeno-Associated Virus Vectors","volume":"5","author":"Fraites","year":"2002","journal-title":"Mol. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.ymthe.2023.02.014","article-title":"Phase I Study of Liver Depot Gene Therapy in Late-Onset Pompe Disease","volume":"31","author":"Smith","year":"2023","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1038\/mtna.2014.1","article-title":"The Dynamics of Compound, Transcript, and Protein Effects After Treatment with 2OMePS Antisense Oligonucleotides in Mdx Mice","volume":"3","author":"Verhaart","year":"2014","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.2353\/ajpath.2008.071042","article-title":"Preservation of Muscle Force in Mdx3cv Mice Correlates with Low-Level Expression of a near Full-Length Dystrophin Protein","volume":"172","author":"Li","year":"2008","journal-title":"Am. J. Pathol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1038\/s41467-025-57481-7","article-title":"AAV9-Mediated MYBPC3 Gene Therapy with Optimized Expression Cassette Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models","volume":"16","author":"Greenwood","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/s41434-025-00524-x","article-title":"Optimization of Adeno-Associated Viral (AAV) Gene Therapies Vectors for Balancing Efficacy, Longevity and Safety for Clinical Application","volume":"32","author":"Mehta","year":"2025","journal-title":"Gene Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.ymthe.2020.07.006","article-title":"Quantification of CpG Motifs in rAAV Genomes: Avoiding the Toll","volume":"28","author":"Wright","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"47","DOI":"10.32607\/actanaturae.11063","article-title":"Muscle-Specific Promoters for Gene Therapy","volume":"13","author":"Skopenkova","year":"2021","journal-title":"Acta Naturae"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"123742","DOI":"10.1016\/j.lfs.2025.123742","article-title":"Combination of miRNA148a-3p Binding Sites and C5\u201312 Promoter in rAAV Vector Synergistically Reduces Antigen Presentation and Transgene Immunity","volume":"376","author":"Huang","year":"2025","journal-title":"Life Sci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-Associated Virus as a Delivery Vector for Gene Therapy of Human Diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"183","DOI":"10.5500\/wjt.v6.i1.183","article-title":"Immunosuppressive Potency of Mechanistic Target of Rapamycin Inhibitors in Solid-Organ Transplantation","volume":"6","author":"Pons","year":"2016","journal-title":"World J. Transplant."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.omtm.2022.07.018","article-title":"Immunogenicity Assessment of AAV-Based Gene Therapies: An IQ Consortium Industry White Paper","volume":"26","author":"Yang","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.omtm.2020.11.016","article-title":"Efficacy of AAV8-hUGT1A1 with Rapamycin in Neonatal, Suckling, and Juvenile Rats to Model Treatment in Pediatric CNs Patients","volume":"20","author":"Shi","year":"2021","journal-title":"Mol. Ther.\u2014Methods Clin. Dev."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1089\/hum.2021.258","article-title":"The Effect of Rapamycin and Ibrutinib on Antibody Responses to Adeno-Associated Virus Vector-Mediated Gene Transfer","volume":"33","author":"Xiang","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/s41434-023-00423-z","article-title":"Prednisolone and Rapamycin Reduce the Plasma Cell Gene Signature and May Improve AAV Gene Therapy in Cynomolgus Macaques","volume":"31","author":"Kistner","year":"2024","journal-title":"Gene Ther."},{"key":"ref_108","unstructured":"University of Florida (2025, August 07). Evaluation of Re-Administration of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase (rAAV9-DES-hGAA) in Patients with Late-Onset Pompe Disease (LOPD); Clinical Trial Registration NCT02240407; Clinicaltrials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT02240407."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1038\/nnano.2016.135","article-title":"Improving the Efficacy and Safety of Biologic Drugs with Tolerogenic Nanoparticles","volume":"11","author":"Kishimoto","year":"2016","journal-title":"Nat. Nanotechnol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.cellimm.2015.11.004","article-title":"Tolerogenic Nanoparticles to Induce Immunologic Tolerance: Prevention and Reversal of FVIII Inhibitor Formation","volume":"301","author":"Zhang","year":"2016","journal-title":"Cell. Immunol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1038\/s41467-018-06621-3","article-title":"Antigen-Selective Modulation of AAV Immunogenicity with Tolerogenic Rapamycin Nanoparticles Enables Successful Vector Re-Administration","volume":"9","author":"Meliani","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"eabd0321","DOI":"10.1126\/sciadv.abd0321","article-title":"Enhancement of Liver-Directed Transgene Expression at Initial and Repeat Doses of AAV Vectors Admixed with ImmTOR Nanoparticles","volume":"7","author":"Ilyinskii","year":"2021","journal-title":"Sci. Adv."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"pgad394","DOI":"10.1093\/pnasnexus\/pgad394","article-title":"Readministration of High-Dose Adeno-Associated Virus Gene Therapy Vectors Enabled by ImmTOR Nanoparticles Combined with B Cell-Targeted Agents","volume":"2","author":"Ilyinskii","year":"2023","journal-title":"PNAS Nexus"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e3509","DOI":"10.1002\/jgm.3509","article-title":"Successful AAV8 Readministration: Suppression of Capsid-Specific Neutralizing Antibodies by a Combination Treatment of Bortezomib and CD20 mAb in a Mouse Model of Pompe Disease","volume":"25","author":"Choi","year":"2023","journal-title":"J. Gene Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"101216","DOI":"10.1016\/j.omtm.2024.101216","article-title":"B Cell Focused Transient Immune Suppression Protocol for Efficient AAV Readministration to the Liver","volume":"32","author":"Rana","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/mt.2012.84","article-title":"Pharmacological Modulation of Humoral Immunity in a Nonhuman Primate Model of AAV Gene Transfer for Hemophilia B","volume":"20","author":"Mingozzi","year":"2012","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1188\/04.CJON.377-382","article-title":"Management of Patients Receiving Antithymocyte Globulin for Aplastic Anemia and Myelodysplastic Syndrome","volume":"8","author":"Bevans","year":"2004","journal-title":"Clin. J. Oncol. Nurs."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1016\/j.ymthe.2024.07.016","article-title":"A Systematic Review of Immunosuppressive Protocols Used in AAV Gene Therapy for Monogenic Disorders","volume":"32","author":"Vrellaku","year":"2024","journal-title":"Mol. Ther."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/1479-5876-10-122","article-title":"Transient and Intensive Pharmacological Immunosuppression Fails to Improve AAV-Based Liver Gene Transfer in Non-Human Primates","volume":"10","author":"Unzu","year":"2012","journal-title":"J. Transl. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.omtm.2020.01.004","article-title":"Successful Transduction with AAV Vectors after Selective Depletion of Anti-AAV Antibodies by Immunoadsorption","volume":"16","author":"Orlowski","year":"2020","journal-title":"Mol. Ther.\u2014Methods Clin. Dev."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/mt.2013.244","article-title":"Plasmapheresis Eliminates the Negative Impact of AAV Antibodies on Microdystrophin Gene Expression Following Vascular Delivery","volume":"22","author":"Chicoine","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1038\/mt.2011.108","article-title":"A 10 Patient Case Report on the Impact of Plasmapheresis Upon Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 6, and 8","volume":"19","author":"Monteilhet","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/bloodadvances.2019000380","article-title":"Immunoadsorption Enables Successful rAAV5-Mediated Repeated Hepatic Gene Delivery in Nonhuman Primates","volume":"3","author":"Salas","year":"2019","journal-title":"Blood Adv."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","article-title":"IgG-Cleaving Endopeptidase Enables in Vivo Gene Therapy in the Presence of Anti-AAV Neutralizing Antibodies","volume":"26","author":"Leborgne","year":"2020","journal-title":"Nat. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.ymgme.2020.12.009","article-title":"IdeS: An Enabling Technology to Overcome the Limitation of Neutralizing Antibodies to AAV Gene Therapy","volume":"132","author":"Alexander","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"ref_126","first-page":"e139881","article-title":"Rescuing AAV Gene Transfer from Neutralizing Antibodies with an IgG-Degrading Enzyme","volume":"5","author":"Elmore","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1016\/j.ymthe.2024.05.004","article-title":"Engineered IgM and IgG Cleaving Enzymes for Mitigating Antibody Neutralization and Complement Activation in AAV Gene Transfer","volume":"32","author":"Smith","year":"2024","journal-title":"Mol. Ther."},{"key":"ref_128","unstructured":"(2025, October 01). Zolgensma\u00ae Global Managed Access Program (gMAP)|Novartis. Available online: https:\/\/www.novartis.com\/healthcare-professionals\/managed-access-programs\/zolgensma-global-managed-access-program-gmap."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1182\/bloodadvances.2024014111","article-title":"Adeno-Associated Virus-Based Gene Therapy for Hemophilia A and B: A Systematic Review and Meta-Analysis","volume":"8","author":"Deshpande","year":"2024","journal-title":"Blood Adv."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Matagne, V., Borloz, E., Ehinger, Y., Saidi, L., Villard, L., and Roux, J.-C. (2021). Severe Offtarget Effects Following Intravenous Delivery of AAV9-MECP2 in a Female Mouse Model of Rett Syndrome. Neurobiol. Dis., 149.","DOI":"10.1016\/j.nbd.2020.105235"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.omtm.2023.06.002","article-title":"Innate and Adaptive AAV-Mediated Immune Responses in a Mouse Model of Duchenne Muscular Dystrophy","volume":"30","author":"Emami","year":"2023","journal-title":"Mol. Ther.\u2014Methods Clin. Dev."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/sj.gt.3302766","article-title":"Long-Term Expression and Repeated Administration of AAV Type 1, 2 and 5 Vectors in Skeletal Muscle of Immunocompetent Adult Mice","volume":"13","author":"Danos","year":"2006","journal-title":"Gene Ther."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.ymthe.2017.05.003","article-title":"Successful Repeated Hepatic Gene Delivery in Mice and Non-Human Primates Achieved by Sequential Administration of AAV5ch and AAV1","volume":"25","author":"Majowicz","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1146\/annurev-virology-101416-041936","article-title":"Overcoming the Host Immune Response to Adeno-Associated Virus Gene Delivery Vectors: The Race Between Clearance, Tolerance, Neutralization, and Escape","volume":"4","author":"Mingozzi","year":"2017","journal-title":"Annu. Rev. Virol."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Weber, T. (2021). Anti-AAV Antibodies in AAV Gene Therapy: Current Challenges and Possible Solutions. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.658399"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"108735","DOI":"10.1016\/j.heares.2023.108735","article-title":"Immune Responses in the Mammalian Inner Ear and Their Implications for AAV-Mediated Inner Ear Gene Therapy","volume":"432","author":"Ishibashi","year":"2023","journal-title":"Hear. Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1089\/humc.2015.068","article-title":"Evaluation of Readministration of a Recombinant Adeno-Associated Virus Vector Expressing Acid Alpha-Glucosidase in Pompe Disease: Preclinical to Clinical Planning","volume":"26","author":"Corti","year":"2015","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41434-022-00371-0","article-title":"Immune Profiling of Adeno-Associated Virus Response Identifies B Cell-Specific Targets That Enable Vector Re-Administration in Mice","volume":"30","author":"Chen","year":"2023","journal-title":"Gene Ther."},{"key":"ref_139","first-page":"e2411062","article-title":"Artificial Intelligence-Based Approaches for AAV Vector Engineering","volume":"12","author":"Tan","year":"2025","journal-title":"Adv. Sci. Weinh. Baden-Wurtt. Ger."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Shiraishi, Y., Adachi, T., Cacicedo, J.M., and Ido, Y. (2022). Development of a High-Yield, High-Quality Purification Process for Adeno-Associated Virus Vectors That Can Be Used in Vivo without Ultracentrifugation: Application to a Lung Endothelial Cell-Targeted Adeno-Associated Virus. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol., 36.","DOI":"10.1096\/fj.202200840RR"},{"key":"ref_141","unstructured":"(2025, November 01). Quality, Non-Clinical and Clinical Issues Relating Specifically to Recombinant Adeno-Associated Viral Vectors\u2014Scientific Guideline|European Medicines Agency (EMA). Available online: https:\/\/www.ema.europa.eu\/en\/quality-non-clinical-clinical-issues-relating-specifically-recombinant-adeno-associated-viral-vectors-scientific-guideline."},{"key":"ref_142","unstructured":"FDA (2025, July 02). Immunogenicity of Gene Therapy Products, Available online: https:\/\/www.fda.gov\/vaccines-blood-biologics\/science-research-biologics\/immunogenicity-gene-therapy-products."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/11\/1492\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T10:13:09Z","timestamp":1763547189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/11\/1492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":142,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["pharmaceutics17111492"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics17111492","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]}}}